Hendrik Jan L. Ankersmit

from Wikipedia, the free encyclopedia
Hendrik Jan L Ankersmit (2019)

Hendrik Jan Leonard Ankersmit (* 1970 in Durban ) is a thoracic surgeon , translational academic researcher and entrepreneur.

life and work

Ankersmit grew up in Johannesburg and Klagenfurt . He studied medicine and philosophy in Vienna, where he received his doctorate in 1994. After a postdoctoral stay at Columbia University (College of Physicians and Surgeons, 1997–1998), he completed specialist training in general, cardiac and thoracic surgery. In 2004 he completed his habilitation at the University of Vienna for cardiothoracic surgery on the subject of "Immunological changes after implantation of artificial hearts". In 1999, Ankersmit established the “Applied Immunology” working group in the research laboratories of the University Clinic for Surgery (FOLAB Chirurgie) at the Medical University of Vienna (MUW).

Scientific work

This article or section needs to be revised: Over-referenced - This is not intended to contain a complete list of publications in the form of individual references, but only the most important works, if applicable.
Please help to improve it , and then remove this flag.

  • First description of leukocyte apoptosis in vivo in the artificial heart, in sepsis, in dialysis and in transplant vasculopathy (1999–2002)
  • First description of a humoral alpha-Gal specific defense reaction in recipients of bio valves (2005,2009)
  • First description of a CD32-mediated platelet aggregation by IVIG and ATG (2003,2008)
  • Definition of alveolar pneumoepithelial cells as main biological producers of sST2 (2010)
  • Redefinition of the immune status after CABG surgery as "immunological anergy" (2005-2014)
  • Definition of chronic obstructive pulmonary disease (COPD) as a cellular autoimmune disease (2009–13)
  • Biomarker research in COPD and lung cancer patients (2009–12) and first description of airtrapping / emphysema in COPD patients with normal lung function (2015).

In 2008, Ankersmit was the scientific founder of Aposcience AG, a Viennese company for regenerative medicine. Ankersmit first described that apoptotic white blood cells (peripheral mononuclear cells, PBMC) and their secretion products almost completely prevent the experimental myocardial infarction. These data call into question the fundamental necessity of using stem cells and their secretion products in regenerative medicine. In 2008 he patented a new group of substances called Aposectm, the secretome of stressed white blood cells. Aposectm is an "investigational drug product" produced according to GMP and approved for clinical studies and belongs to the group of substances called "biologicals". In multiple preclinical experiments, Aposectm demonstrated a cytoprotective and regenerative effect in vitro and vivo. The cell-free secretion product prevents damage and promotes healing in the case of heart attacks, myocarditis, strokes, spinal cord trauma and skin wounds in experimental models. In 2014/15, ARGE Ankersmit carried out the world's first monitored, PBMC secretome-based phase I regeneration study with an autologous test substance in an acute wound model.

Publications

  • with Stefan Hacker , Ernst Wolner and Walter Klepetko : Ethical and Psychological Aspects of Organ Explantation , in: Michael Fischer / Kurt Zänker (eds.): Medical and Bioethics. Peter Lang, Verlag Frankfurt / Main 2006.
  • Science and business deserve a chance: Comments from others . Der Standard, December 26, 2013
  • with Helmut Hofbauer, Lukas Kaelin, Walter Feigl. Is the patient human? Anthology, LIT Verlag, Münster 2015
  • with Helmut Hofbauer: Hegemon and Science , in: Stephan Kirste, Hanna Maria Kreuzbauer, Ingeborg Schrems, Michaela Strasser and Silvia Traunwieser (eds.): The art of dialogue. Commemorative letter for Michael Fischer. Peter Lang Verlag, Frankfurt / Main / Vienna 2017.

Individual evidence

  1. ^ J Thorac Cardiovasc Surg. 2002 Mar; 123 (3): 557-61. doi: 10.1067 / mtc.2002.120011.
  2. ↑ Lancet. 1999 Aug 14; 354 ​​(9178): 550-5.doi: 10.1016 / S0140-6736 (98) 10359-8.
  3. ↑ Biochem Biophys Res Commun. 2003 Sep 5; 308 (4): 840-6. doi: 10.1016 / S0006-291X (03) 01482-7.
  4. ↑ Biochem Biophys Res Commun. 2003 Aug 29; 308 (3): 581-5. doi: 10.1016 / S0006-291X (03) 01389-5.
  5. ^ Clin Exp Immunol. 2002 Jan; 127 (1): 183-9. doi: 10.1046 / j.1365-2249.2002.01741.x.
  6. ↑ Eur J Clin Invest. 2005 Jan; 35 (1): 17-23. doi: 10.1111 / j.1365-2362.2005.01441.x.
  7. ↑ Thorac Cardiovasc Surg. 2009 Jun; 57 (4): 191-5. doi: 10.1055 / s-0029-1185395.
  8. ↑ Am J Transplant. 2003 Jun; 3 (6): 754-9.doi: 10.1034 / j.1600-6143.2003.00150.x.
  9. ↑ Br J Dermatol. 2008 Sep; 159 (3): 578-84. doi: 10.1111 / j.1365-2133.2008.08700.x.
  10. ↑ Cardiovasc Res. 2010 Sep 1; 87 (4): 769-77. doi: 10.1093 / cvr / cvq104.
  11. ^ Clin Lab. 2005; 51 (11-12): 657-63.
  12. ^ Clin Lab. 2006; 52 (5-6): 255-61.
  13. ↑ Ann Thorac Surg. 2008 Jan; 85 (1): 80-7. doi: 10.1016 / j.athoracsur.2007.06.049.
  14. ↑ Eur J Cardiothorac Surg. 2013 Aug; 44 (2): 282-7. doi: 10.1093 / ejcts / ezs659.
  15. ^ J Cardiovasc Surg (Torino). 2014 Dec; 55 (6): 849-56.
  16. ^ Clin Exp Immunol. 2009 Mar; 155 (3): 466-75. doi: 10.1111 / j.1365-2249.2008.03835.x.
  17. ↑ Vienna Klin Wochenschr. 2013 Mar; 125 (5-6): 150-5. doi: 10.1007 / s00508-013-0340-4.
  18. ^ Clin Lab. 2009; 55 (1-2): 31-40.
  19. ^ J Clin Lab Anal. 2009; 23 (6): 372-9. doi: 10.1002 / jcla.20348.
  20. ^ Clin Chim Acta. 2012 Jul 11; 413 (13-14): 1115-20. doi: 10.1016 / j.cca.2012.03.008.
  21. ↑ Clin Respir J. 2015 Jul; 9 (3): 375-9. doi: 10.1111 / crj.12139.
  22. ↑ Eur J Clin Invest. 2009 Jun; 39 (6): 445-56. doi: 10.1111 / j.1365-2362.2009.02111.x. Epub 2009 Apr 16.
  23. ^ Basic Res Cardiol. 2011 Nov; 106 (6): 1283-97. doi: 10.1007 / s00395-011-0224-6. Epub 2011 Sep 28.
  24. ↑ Eur Heart J. 2015 Mar 14; 36 (11): 676-85. doi: 10.1093 / eurheartj / ehs459. Epub 2013 Jan 14.
  25. ↑ Version 2. F1000Res. 2014 Jun 19 [revised 2014 Oct 28]; 3: 131. doi: 10.12688 / f1000research.4219.2. eCollection 2014
  26. ^ Exp Neurol. 2015 May; 267: 230-42. doi: 10.1016 / j.expneurol.2015.03.013. Epub 2015 Mar 19.
  27. ↑ PLoS One. 2013; 8 (3): e60103. doi: 10.1371 / journal.pone.0060103. Epub 2013 Mar 22.
  28. ^ Sci Rep. 2016 Apr 29; 6: 25168. doi: 10.1038 / srep25168.
  29. ↑ apoptosis. 2016 Dec; 21 (12): 1336-1353.
  30. ↑ Ann Transl Med. 2017 Apr; 5 (7): 170. doi: 10.21037 / atm.2017.03.50
  31. ↑ Sci Rep. 2017 Jul 24; 7 (1): 6216. doi: 10.1038 / s41598-017-06223-x.
personal data
SURNAME Ankersmit, Hendrik Jan L.
ALTERNATIVE NAMES Ankersmit, Hendrik Jan Leonard
BRIEF DESCRIPTION Thoracic surgeon and entrepreneur
DATE OF BIRTH 1970
PLACE OF BIRTH Durban , South Africa